


Figure 3. Predicted susceptibility to various NRTIs and NNRTIs during ART failure in 128 cases, Libya, 2014–2017



NRTIs: Nucleoside reverse transcriptase inhibitors; NNRTIs: Non-nucleoside reverse transcriptase inhibitors; ART: Antiretroviral therapy; 3TC: Lamivudine; ABC: Abacavir; AZT: Zidovudine; D4T: Stavudine; DDI: Didanosine; FTC: Emtricitabine; TDF: Tenofovir; EFV: Efavirenz; NVP: Nevirapine; ETR: Etravirine; RPV: Rilpivirine; DOR: Doravirine